Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/14740338.2016.1175430 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cigarette smoking and symptom burden: baseline results from 9 ECOG-ACRIN cancer clinical trials.
J Pain Symptom Manage
December 2024
Wake Forest University School of Medicine, Winston-Salem, NC; University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC.
Context: Approximately 11% of cancer survivors smoke post-diagnosis.
Objective: Understanding the relationship between smoking and perceived cancer-related symptoms may inform tobacco treatment interventions for this population.
Methods: From 2017-2021, 740 adults in 9 ECOG-ACRIN trials provided baseline data.
Real-world evidence of adjuvant immunotherapy in resected stage III and IV melanoma patients: CADIM trial final results. Experience from 2 tertiary referral centers.
Actas Dermosifiliogr
December 2024
Servicio de Oncología Médica, Hospital Clínico Universitario Virgen de la Arrixaca, Ciudad de Murcia, Spain; Instituto Murciano de Investigación Biosanitaria (IMIB), Spain.
Introduction: Clinical trials have validated the use of nivolumab and pembrolizumab as adjuvant therapies regarding relapse-free survival (RFS) in patients with resected stage III and IV melanoma. Evidence in real-world patients is currently limited.
Material And Method: The CADIM trial (Characterization of adjuvant immunotherapy in melanoma patients) recruited a total of 81 patients with resected stage III and IV melanoma on nivolumab or pembrolizumab as adjuvant therapy from February 2018 through December 2022.
Advances in cancer treatments have significantly improved their effectiveness, yet access to first-line therapies remains limited. A 2017 survey revealed that over 25 % of metastatic melanoma patients in Europe lacked access to recommended therapies. To address this, the European Association of Dermato-Oncology and the European Melanoma Registry conducted a follow-up study on the registration and reimbursement of first-line treatments.
View Article and Find Full Text PDFThromboembolic events associated with immune checkpoint inhibitors in cancer patients: A Bayesian network meta-analysis.
Thromb Res
December 2024
Department of Oncology Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, China. Electronic address:
Background: Immune checkpoint inhibitors (ICIs), which offer previously unknown therapeutic advantages, have revolutionized cancer treatment. However, the risk of thromboembolic events (TEEs) associated with ICIs remains unclear. The aim of this network meta-analysis (NMA) was to evaluate the incidence of TEEs in cancer patients receiving different treatment regimens.
View Article and Find Full Text PDFSarcoidosis-Like Reaction in Melanoma Patients Receiving Immunotherapy or Targeted Therapy.
Case Rep Oncol Med
December 2024
Oncology Unit Fondazione, IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
This case series highlights the complexity of sarcoidosis-like reactions (SLRs) during cancer treatment, specifically in patients receiving immunotherapy or targeted therapies for melanoma. SLRs can either mimic disease progression or present as part of the clinical manifestation, making diagnosis and treatment challenging. Our study reviewed the medical records of 31 patients who were candidates for postoperative treatment between June 2022 and June 2024.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!